StonvexLoading…
StonvexStonvexStonvexCore line items from IBIO's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-06-30 | Annual 2024 2024-06-30 | Annual 2023 2023-06-30 |
|---|---|---|---|
Revenue | $400.00K | $225.00K | $0.00 |
Operating Income | $-18.60M | $-16.63M | $-29.34M |
Net Income | $-18.38M | $-24.91M | $-65.01M |
EPS (Diluted) | $-1.75 | $-6.50 | $-106.19 |
Total Assets | $23.18M | $28.73M | $41.21M |
Total Liabilities | $8.30M | $7.41M | $25.83M |
Cash & Equivalents | $8.58M | $14.21M | $4.30M |
Free Cash Flow OCF − CapEx | $-15.32M | $-18.76M | $-36.17M |
Shares Outstanding | 19.35M | 8.62M | 1.02M |